Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

BACKGROUND: The ToGA study showed that trastuzumab plus chemotherapy prolonged median survival in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. Among chemotherapy options, oxaliplatin might be as effective as cisplatin but has shown to be more tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jifang, Liu, Tianshu, Fan, Qingxia, Bai, Li, Bi, Feng, Qin, Shukui, Wang, Jinwan, Xu, Nong, Cheng, Ying, Bai, Yuxian, Liu, Wei, Wang, Liwei, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746787/
https://www.ncbi.nlm.nih.gov/pubmed/26857702
http://dx.doi.org/10.1186/s12885-016-2092-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746787/
https://www.ncbi.nlm.nih.gov/pubmed/26857702
http://dx.doi.org/10.1186/s12885-016-2092-9

Ejemplares similares